First Multi-Coronavirus Vaccine Enters Human Testing, Built on University of Washington Institute for Protein Design Technology

A new vaccine designed to protect against multiple coronaviruses has begun Phase 1/2 clinical trials in Australia. Led by SK bioscience with support from CEPI, the program uses University of Washington-developed, AI-assisted protein nanoparticle technology to target sarbecoviruses, including COVID-19, SARS, MERS, and related animal-borne threats.